photo
Speaker

Marianne De Backer, MBA;MSc;PhD

EVP, HEAD OF BUSINESS DEVELOPMENT AND LICENSING, BAYER PHARMACEUTICALS
Berlin, Germany
Marianne De Backer has been a strategist, scientist, business leader, deal maker, and corporate investor in the healthcare industry for more than two decades. Her network spans across pharmaceutical, biotech, tech, academia, VC, NGO, and government partners worldwide. She has been directly accountable for more than 200 strategic alliances in healthcare, some of which have led to newly approved medicines that are now available to patients. Since 2019, she is a member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development & Licensing and Open Innovation of the Bayer AG (BAYRY) Pharmaceuticals division. Dr. De Backer is spearheading the external innovation growth agenda, resulting in more than 40 new alliances and the acquisitions of Vividion Therapeutics, Noria and PSMA Therapeutics in 2021, and Asklepios Biopharmaceutical and KaNDy Therapeutics in 2020. In 2021, she was recognized as one of the Fiercest Women in Life Sciences. As a passionate champion for inclusion and diversity, she recently launched I&DXcelerate in Bayer, a program to accelerate the development of diverse talent.
Prior to that, Dr. De Backer was at Johnson & Johnson where she last held global Corporate Development and Venture Investor roles, including the position of global Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group based out of Silicon Valley. Earlier she led a commercial business unit in Europe, launching drugs in neuroscience and immunology. Dr. De Backer started her career in drug discovery research, leading teams in both Europe and the United States and is an inventor on seven patents.
Dr. De Backer serves as a non-executive Director on the boards of Gladstone Foundation, Kronos Bio (KRON) and Arrowhead Pharmaceuticals (ARWR). She holds an MBA from Erasmus University Rotterdam, The Netherlands; Master in Molecular Biology from Vrije Universiteit, Brussels; Master in Engineering Biochemistry and a PhD in Biotechnology, both from Ghent University, Belgium.

Dr. De Backer serves as a non-executive Director on the boards of Gladstone Foundation, Kronos Bio (KRON) and Arrowhead Pharmaceuticals (ARWR). She holds an MBA from Erasmus University Rotterdam, The Netherlands; Master in Molecular Biology from Vrije Universiteit, Brussels; Master in Engineering Biochemistry and a PhD in Biotechnology, both from Ghent University, Belgium.
Speaking In
1:00 PM - 2:00 PM (PDT)
Monday, June 13
When Vividion examined the next steps for their company, an IPO was the path forward. Until one day…
12:15 PM - 1:30 PM (PDT)
Tuesday, June 14
The unprecedented venture funding into promising biotechs and public market performance in biotechs…
3:25 PM - 3:35 PM (PDT)
Tuesday, June 14
Interview: Marieanne De Backer, EVP  & Head of Business Development and Licensing
11:00 AM - 12:00 PM (PDT)
Wednesday, June 15
Protein degradation has emerged as one of the hottest areas of therapeutic research. Harnessing the…